nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—CYP1A1—Methoxsalen—hematologic cancer	0.106	0.191	CbGbCtD
Dicyclomine—CYP1A1—Bortezomib—hematologic cancer	0.101	0.181	CbGbCtD
Dicyclomine—CYP1A1—Daunorubicin—hematologic cancer	0.0969	0.173	CbGbCtD
Dicyclomine—CYP1A1—Thalidomide—hematologic cancer	0.0882	0.158	CbGbCtD
Dicyclomine—CYP1A1—Dacarbazine—hematologic cancer	0.0759	0.136	CbGbCtD
Dicyclomine—CYP1A1—Dasatinib—hematologic cancer	0.0596	0.107	CbGbCtD
Dicyclomine—CYP1A1—Dexamethasone—hematologic cancer	0.0305	0.0546	CbGbCtD
Dicyclomine—Rash—Vincristine—hematologic cancer	7.99e-05	0.000218	CcSEcCtD
Dicyclomine—Dermatitis—Vincristine—hematologic cancer	7.99e-05	0.000218	CcSEcCtD
Dicyclomine—Pain—Triamcinolone—hematologic cancer	7.97e-05	0.000218	CcSEcCtD
Dicyclomine—Headache—Vincristine—hematologic cancer	7.94e-05	0.000217	CcSEcCtD
Dicyclomine—Loss of consciousness—Prednisone—hematologic cancer	7.93e-05	0.000216	CcSEcCtD
Dicyclomine—Nausea—Carmustine—hematologic cancer	7.89e-05	0.000215	CcSEcCtD
Dicyclomine—Vomiting—Irinotecan—hematologic cancer	7.85e-05	0.000214	CcSEcCtD
Dicyclomine—Vomiting—Mitoxantrone—hematologic cancer	7.85e-05	0.000214	CcSEcCtD
Dicyclomine—Immune system disorder—Methotrexate—hematologic cancer	7.82e-05	0.000214	CcSEcCtD
Dicyclomine—Nausea—Alitretinoin—hematologic cancer	7.82e-05	0.000213	CcSEcCtD
Dicyclomine—Mediastinal disorder—Methotrexate—hematologic cancer	7.8e-05	0.000213	CcSEcCtD
Dicyclomine—Hypertension—Prednisone—hematologic cancer	7.79e-05	0.000213	CcSEcCtD
Dicyclomine—Rash—Mitoxantrone—hematologic cancer	7.79e-05	0.000213	CcSEcCtD
Dicyclomine—Rash—Irinotecan—hematologic cancer	7.79e-05	0.000213	CcSEcCtD
Dicyclomine—Dermatitis—Mitoxantrone—hematologic cancer	7.78e-05	0.000212	CcSEcCtD
Dicyclomine—Dermatitis—Irinotecan—hematologic cancer	7.78e-05	0.000212	CcSEcCtD
Dicyclomine—Headache—Mitoxantrone—hematologic cancer	7.74e-05	0.000211	CcSEcCtD
Dicyclomine—Headache—Irinotecan—hematologic cancer	7.74e-05	0.000211	CcSEcCtD
Dicyclomine—Nausea—Ifosfamide—hematologic cancer	7.72e-05	0.000211	CcSEcCtD
Dicyclomine—Feeling abnormal—Triamcinolone—hematologic cancer	7.68e-05	0.00021	CcSEcCtD
Dicyclomine—Vomiting—Gemcitabine—hematologic cancer	7.65e-05	0.000209	CcSEcCtD
Dicyclomine—Insomnia—Dexamethasone—hematologic cancer	7.65e-05	0.000209	CcSEcCtD
Dicyclomine—Insomnia—Betamethasone—hematologic cancer	7.65e-05	0.000209	CcSEcCtD
Dicyclomine—Paraesthesia—Dexamethasone—hematologic cancer	7.59e-05	0.000207	CcSEcCtD
Dicyclomine—Paraesthesia—Betamethasone—hematologic cancer	7.59e-05	0.000207	CcSEcCtD
Dicyclomine—Discomfort—Prednisone—hematologic cancer	7.59e-05	0.000207	CcSEcCtD
Dicyclomine—Mental disorder—Methotrexate—hematologic cancer	7.59e-05	0.000207	CcSEcCtD
Dicyclomine—Rash—Gemcitabine—hematologic cancer	7.58e-05	0.000207	CcSEcCtD
Dicyclomine—Dermatitis—Gemcitabine—hematologic cancer	7.58e-05	0.000207	CcSEcCtD
Dicyclomine—Eye disorder—Epirubicin—hematologic cancer	7.57e-05	0.000207	CcSEcCtD
Dicyclomine—Hypersensitivity—Etoposide—hematologic cancer	7.57e-05	0.000207	CcSEcCtD
Dicyclomine—Erythema—Methotrexate—hematologic cancer	7.54e-05	0.000206	CcSEcCtD
Dicyclomine—Headache—Gemcitabine—hematologic cancer	7.54e-05	0.000206	CcSEcCtD
Dicyclomine—Nausea—Vincristine—hematologic cancer	7.53e-05	0.000206	CcSEcCtD
Dicyclomine—Cardiac disorder—Epirubicin—hematologic cancer	7.52e-05	0.000205	CcSEcCtD
Dicyclomine—Hypersensitivity—Prednisolone—hematologic cancer	7.46e-05	0.000204	CcSEcCtD
Dicyclomine—Hypoaesthesia—Doxorubicin—hematologic cancer	7.46e-05	0.000204	CcSEcCtD
Dicyclomine—Dyspepsia—Betamethasone—hematologic cancer	7.44e-05	0.000203	CcSEcCtD
Dicyclomine—Dyspepsia—Dexamethasone—hematologic cancer	7.44e-05	0.000203	CcSEcCtD
Dicyclomine—Urticaria—Triamcinolone—hematologic cancer	7.4e-05	0.000202	CcSEcCtD
Dicyclomine—Asthenia—Etoposide—hematologic cancer	7.37e-05	0.000201	CcSEcCtD
Dicyclomine—Oedema—Prednisone—hematologic cancer	7.36e-05	0.000201	CcSEcCtD
Dicyclomine—Anaphylactic shock—Prednisone—hematologic cancer	7.36e-05	0.000201	CcSEcCtD
Dicyclomine—Decreased appetite—Betamethasone—hematologic cancer	7.35e-05	0.000201	CcSEcCtD
Dicyclomine—Decreased appetite—Dexamethasone—hematologic cancer	7.35e-05	0.000201	CcSEcCtD
Dicyclomine—Nausea—Mitoxantrone—hematologic cancer	7.33e-05	0.0002	CcSEcCtD
Dicyclomine—Nausea—Irinotecan—hematologic cancer	7.33e-05	0.0002	CcSEcCtD
Dicyclomine—Immune system disorder—Epirubicin—hematologic cancer	7.32e-05	0.0002	CcSEcCtD
Dicyclomine—Mediastinal disorder—Epirubicin—hematologic cancer	7.3e-05	0.000199	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Betamethasone—hematologic cancer	7.3e-05	0.000199	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	7.3e-05	0.000199	CcSEcCtD
Dicyclomine—Fatigue—Betamethasone—hematologic cancer	7.29e-05	0.000199	CcSEcCtD
Dicyclomine—Fatigue—Dexamethasone—hematologic cancer	7.29e-05	0.000199	CcSEcCtD
Dicyclomine—Pruritus—Etoposide—hematologic cancer	7.27e-05	0.000198	CcSEcCtD
Dicyclomine—Shock—Prednisone—hematologic cancer	7.24e-05	0.000198	CcSEcCtD
Dicyclomine—Pain—Dexamethasone—hematologic cancer	7.23e-05	0.000197	CcSEcCtD
Dicyclomine—Pain—Betamethasone—hematologic cancer	7.23e-05	0.000197	CcSEcCtD
Dicyclomine—Nervous system disorder—Prednisone—hematologic cancer	7.22e-05	0.000197	CcSEcCtD
Dicyclomine—Tachycardia—Prednisone—hematologic cancer	7.18e-05	0.000196	CcSEcCtD
Dicyclomine—Nausea—Gemcitabine—hematologic cancer	7.14e-05	0.000195	CcSEcCtD
Dicyclomine—Vomiting—Cisplatin—hematologic cancer	7.13e-05	0.000195	CcSEcCtD
Dicyclomine—Vision blurred—Methotrexate—hematologic cancer	7.1e-05	0.000194	CcSEcCtD
Dicyclomine—Mental disorder—Epirubicin—hematologic cancer	7.1e-05	0.000194	CcSEcCtD
Dicyclomine—Rash—Cisplatin—hematologic cancer	7.07e-05	0.000193	CcSEcCtD
Dicyclomine—Dermatitis—Cisplatin—hematologic cancer	7.06e-05	0.000193	CcSEcCtD
Dicyclomine—Erythema—Epirubicin—hematologic cancer	7.05e-05	0.000193	CcSEcCtD
Dicyclomine—Anorexia—Prednisone—hematologic cancer	7.02e-05	0.000192	CcSEcCtD
Dicyclomine—Eye disorder—Doxorubicin—hematologic cancer	7.01e-05	0.000191	CcSEcCtD
Dicyclomine—Ill-defined disorder—Methotrexate—hematologic cancer	6.99e-05	0.000191	CcSEcCtD
Dicyclomine—Feeling abnormal—Betamethasone—hematologic cancer	6.97e-05	0.00019	CcSEcCtD
Dicyclomine—Feeling abnormal—Dexamethasone—hematologic cancer	6.97e-05	0.00019	CcSEcCtD
Dicyclomine—Cardiac disorder—Doxorubicin—hematologic cancer	6.96e-05	0.00019	CcSEcCtD
Dicyclomine—Tension—Epirubicin—hematologic cancer	6.92e-05	0.000189	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Dexamethasone—hematologic cancer	6.91e-05	0.000189	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Betamethasone—hematologic cancer	6.91e-05	0.000189	CcSEcCtD
Dicyclomine—Hypersensitivity—Triamcinolone—hematologic cancer	6.86e-05	0.000187	CcSEcCtD
Dicyclomine—Nervousness—Epirubicin—hematologic cancer	6.85e-05	0.000187	CcSEcCtD
Dicyclomine—Malaise—Methotrexate—hematologic cancer	6.8e-05	0.000186	CcSEcCtD
Dicyclomine—Dizziness—Etoposide—hematologic cancer	6.79e-05	0.000185	CcSEcCtD
Dicyclomine—Immune system disorder—Doxorubicin—hematologic cancer	6.77e-05	0.000185	CcSEcCtD
Dicyclomine—Mediastinal disorder—Doxorubicin—hematologic cancer	6.76e-05	0.000185	CcSEcCtD
Dicyclomine—Urticaria—Dexamethasone—hematologic cancer	6.72e-05	0.000183	CcSEcCtD
Dicyclomine—Urticaria—Betamethasone—hematologic cancer	6.72e-05	0.000183	CcSEcCtD
Dicyclomine—Dizziness—Prednisolone—hematologic cancer	6.7e-05	0.000183	CcSEcCtD
Dicyclomine—Asthenia—Triamcinolone—hematologic cancer	6.68e-05	0.000183	CcSEcCtD
Dicyclomine—Abdominal pain—Dexamethasone—hematologic cancer	6.68e-05	0.000182	CcSEcCtD
Dicyclomine—Abdominal pain—Betamethasone—hematologic cancer	6.68e-05	0.000182	CcSEcCtD
Dicyclomine—Nausea—Cisplatin—hematologic cancer	6.66e-05	0.000182	CcSEcCtD
Dicyclomine—Insomnia—Prednisone—hematologic cancer	6.66e-05	0.000182	CcSEcCtD
Dicyclomine—Vision blurred—Epirubicin—hematologic cancer	6.65e-05	0.000182	CcSEcCtD
Dicyclomine—Paraesthesia—Prednisone—hematologic cancer	6.61e-05	0.000181	CcSEcCtD
Dicyclomine—Pruritus—Triamcinolone—hematologic cancer	6.59e-05	0.00018	CcSEcCtD
Dicyclomine—Mental disorder—Doxorubicin—hematologic cancer	6.57e-05	0.000179	CcSEcCtD
Dicyclomine—Ill-defined disorder—Epirubicin—hematologic cancer	6.55e-05	0.000179	CcSEcCtD
Dicyclomine—Vomiting—Etoposide—hematologic cancer	6.53e-05	0.000178	CcSEcCtD
Dicyclomine—Erythema—Doxorubicin—hematologic cancer	6.53e-05	0.000178	CcSEcCtD
Dicyclomine—Agitation—Epirubicin—hematologic cancer	6.48e-05	0.000177	CcSEcCtD
Dicyclomine—Dyspepsia—Prednisone—hematologic cancer	6.48e-05	0.000177	CcSEcCtD
Dicyclomine—Rash—Etoposide—hematologic cancer	6.48e-05	0.000177	CcSEcCtD
Dicyclomine—Dermatitis—Etoposide—hematologic cancer	6.47e-05	0.000177	CcSEcCtD
Dicyclomine—Headache—Etoposide—hematologic cancer	6.43e-05	0.000176	CcSEcCtD
Dicyclomine—Tension—Doxorubicin—hematologic cancer	6.41e-05	0.000175	CcSEcCtD
Dicyclomine—Decreased appetite—Prednisone—hematologic cancer	6.4e-05	0.000175	CcSEcCtD
Dicyclomine—Rash—Prednisolone—hematologic cancer	6.39e-05	0.000174	CcSEcCtD
Dicyclomine—Dermatitis—Prednisolone—hematologic cancer	6.38e-05	0.000174	CcSEcCtD
Dicyclomine—Malaise—Epirubicin—hematologic cancer	6.36e-05	0.000174	CcSEcCtD
Dicyclomine—Fatigue—Prednisone—hematologic cancer	6.35e-05	0.000173	CcSEcCtD
Dicyclomine—Headache—Prednisolone—hematologic cancer	6.35e-05	0.000173	CcSEcCtD
Dicyclomine—Discomfort—Methotrexate—hematologic cancer	6.34e-05	0.000173	CcSEcCtD
Dicyclomine—Nervousness—Doxorubicin—hematologic cancer	6.34e-05	0.000173	CcSEcCtD
Dicyclomine—Syncope—Epirubicin—hematologic cancer	6.33e-05	0.000173	CcSEcCtD
Dicyclomine—Constipation—Prednisone—hematologic cancer	6.29e-05	0.000172	CcSEcCtD
Dicyclomine—Palpitations—Epirubicin—hematologic cancer	6.23e-05	0.00017	CcSEcCtD
Dicyclomine—Confusional state—Methotrexate—hematologic cancer	6.2e-05	0.000169	CcSEcCtD
Dicyclomine—Loss of consciousness—Epirubicin—hematologic cancer	6.2e-05	0.000169	CcSEcCtD
Dicyclomine—Dizziness—Triamcinolone—hematologic cancer	6.16e-05	0.000168	CcSEcCtD
Dicyclomine—Anaphylactic shock—Methotrexate—hematologic cancer	6.15e-05	0.000168	CcSEcCtD
Dicyclomine—Vision blurred—Doxorubicin—hematologic cancer	6.15e-05	0.000168	CcSEcCtD
Dicyclomine—Nausea—Etoposide—hematologic cancer	6.1e-05	0.000167	CcSEcCtD
Dicyclomine—Hypertension—Epirubicin—hematologic cancer	6.09e-05	0.000166	CcSEcCtD
Dicyclomine—Feeling abnormal—Prednisone—hematologic cancer	6.07e-05	0.000166	CcSEcCtD
Dicyclomine—Asthenia—Dexamethasone—hematologic cancer	6.06e-05	0.000166	CcSEcCtD
Dicyclomine—Asthenia—Betamethasone—hematologic cancer	6.06e-05	0.000166	CcSEcCtD
Dicyclomine—Ill-defined disorder—Doxorubicin—hematologic cancer	6.06e-05	0.000165	CcSEcCtD
Dicyclomine—Nervous system disorder—Methotrexate—hematologic cancer	6.03e-05	0.000165	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Prednisone—hematologic cancer	6.02e-05	0.000164	CcSEcCtD
Dicyclomine—Nausea—Prednisolone—hematologic cancer	6.02e-05	0.000164	CcSEcCtD
Dicyclomine—Agitation—Doxorubicin—hematologic cancer	6e-05	0.000164	CcSEcCtD
Dicyclomine—Pruritus—Dexamethasone—hematologic cancer	5.98e-05	0.000163	CcSEcCtD
Dicyclomine—Pruritus—Betamethasone—hematologic cancer	5.98e-05	0.000163	CcSEcCtD
Dicyclomine—Discomfort—Epirubicin—hematologic cancer	5.93e-05	0.000162	CcSEcCtD
Dicyclomine—Vomiting—Triamcinolone—hematologic cancer	5.92e-05	0.000162	CcSEcCtD
Dicyclomine—Malaise—Doxorubicin—hematologic cancer	5.89e-05	0.000161	CcSEcCtD
Dicyclomine—Rash—Triamcinolone—hematologic cancer	5.87e-05	0.00016	CcSEcCtD
Dicyclomine—Dry mouth—Epirubicin—hematologic cancer	5.87e-05	0.00016	CcSEcCtD
Dicyclomine—Dermatitis—Triamcinolone—hematologic cancer	5.87e-05	0.00016	CcSEcCtD
Dicyclomine—Anorexia—Methotrexate—hematologic cancer	5.86e-05	0.00016	CcSEcCtD
Dicyclomine—Syncope—Doxorubicin—hematologic cancer	5.85e-05	0.00016	CcSEcCtD
Dicyclomine—Urticaria—Prednisone—hematologic cancer	5.85e-05	0.00016	CcSEcCtD
Dicyclomine—Headache—Triamcinolone—hematologic cancer	5.84e-05	0.000159	CcSEcCtD
Dicyclomine—Abdominal pain—Prednisone—hematologic cancer	5.82e-05	0.000159	CcSEcCtD
Dicyclomine—Confusional state—Epirubicin—hematologic cancer	5.81e-05	0.000159	CcSEcCtD
Dicyclomine—Palpitations—Doxorubicin—hematologic cancer	5.77e-05	0.000158	CcSEcCtD
Dicyclomine—Oedema—Epirubicin—hematologic cancer	5.76e-05	0.000157	CcSEcCtD
Dicyclomine—Anaphylactic shock—Epirubicin—hematologic cancer	5.76e-05	0.000157	CcSEcCtD
Dicyclomine—Loss of consciousness—Doxorubicin—hematologic cancer	5.74e-05	0.000157	CcSEcCtD
Dicyclomine—Shock—Epirubicin—hematologic cancer	5.66e-05	0.000155	CcSEcCtD
Dicyclomine—Nervous system disorder—Epirubicin—hematologic cancer	5.65e-05	0.000154	CcSEcCtD
Dicyclomine—Hypertension—Doxorubicin—hematologic cancer	5.64e-05	0.000154	CcSEcCtD
Dicyclomine—Tachycardia—Epirubicin—hematologic cancer	5.62e-05	0.000153	CcSEcCtD
Dicyclomine—Dizziness—Dexamethasone—hematologic cancer	5.59e-05	0.000153	CcSEcCtD
Dicyclomine—Dizziness—Betamethasone—hematologic cancer	5.59e-05	0.000153	CcSEcCtD
Dicyclomine—Insomnia—Methotrexate—hematologic cancer	5.56e-05	0.000152	CcSEcCtD
Dicyclomine—Nausea—Triamcinolone—hematologic cancer	5.53e-05	0.000151	CcSEcCtD
Dicyclomine—Paraesthesia—Methotrexate—hematologic cancer	5.52e-05	0.000151	CcSEcCtD
Dicyclomine—Discomfort—Doxorubicin—hematologic cancer	5.49e-05	0.00015	CcSEcCtD
Dicyclomine—Anorexia—Epirubicin—hematologic cancer	5.49e-05	0.00015	CcSEcCtD
Dicyclomine—Dyspnoea—Methotrexate—hematologic cancer	5.48e-05	0.00015	CcSEcCtD
Dicyclomine—Somnolence—Methotrexate—hematologic cancer	5.47e-05	0.000149	CcSEcCtD
Dicyclomine—Dry mouth—Doxorubicin—hematologic cancer	5.43e-05	0.000148	CcSEcCtD
Dicyclomine—Hypersensitivity—Prednisone—hematologic cancer	5.42e-05	0.000148	CcSEcCtD
Dicyclomine—Dyspepsia—Methotrexate—hematologic cancer	5.42e-05	0.000148	CcSEcCtD
Dicyclomine—Vomiting—Betamethasone—hematologic cancer	5.37e-05	0.000147	CcSEcCtD
Dicyclomine—Vomiting—Dexamethasone—hematologic cancer	5.37e-05	0.000147	CcSEcCtD
Dicyclomine—Confusional state—Doxorubicin—hematologic cancer	5.37e-05	0.000147	CcSEcCtD
Dicyclomine—Decreased appetite—Methotrexate—hematologic cancer	5.35e-05	0.000146	CcSEcCtD
Dicyclomine—Rash—Dexamethasone—hematologic cancer	5.33e-05	0.000146	CcSEcCtD
Dicyclomine—Rash—Betamethasone—hematologic cancer	5.33e-05	0.000146	CcSEcCtD
Dicyclomine—Oedema—Doxorubicin—hematologic cancer	5.33e-05	0.000145	CcSEcCtD
Dicyclomine—Anaphylactic shock—Doxorubicin—hematologic cancer	5.33e-05	0.000145	CcSEcCtD
Dicyclomine—Dermatitis—Betamethasone—hematologic cancer	5.32e-05	0.000145	CcSEcCtD
Dicyclomine—Dermatitis—Dexamethasone—hematologic cancer	5.32e-05	0.000145	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.31e-05	0.000145	CcSEcCtD
Dicyclomine—Fatigue—Methotrexate—hematologic cancer	5.3e-05	0.000145	CcSEcCtD
Dicyclomine—Headache—Dexamethasone—hematologic cancer	5.3e-05	0.000145	CcSEcCtD
Dicyclomine—Headache—Betamethasone—hematologic cancer	5.3e-05	0.000145	CcSEcCtD
Dicyclomine—Asthenia—Prednisone—hematologic cancer	5.28e-05	0.000144	CcSEcCtD
Dicyclomine—Pain—Methotrexate—hematologic cancer	5.26e-05	0.000144	CcSEcCtD
Dicyclomine—Shock—Doxorubicin—hematologic cancer	5.24e-05	0.000143	CcSEcCtD
Dicyclomine—Nervous system disorder—Doxorubicin—hematologic cancer	5.22e-05	0.000143	CcSEcCtD
Dicyclomine—Pruritus—Prednisone—hematologic cancer	5.21e-05	0.000142	CcSEcCtD
Dicyclomine—Insomnia—Epirubicin—hematologic cancer	5.21e-05	0.000142	CcSEcCtD
Dicyclomine—Tachycardia—Doxorubicin—hematologic cancer	5.2e-05	0.000142	CcSEcCtD
Dicyclomine—Paraesthesia—Epirubicin—hematologic cancer	5.17e-05	0.000141	CcSEcCtD
Dicyclomine—Dyspnoea—Epirubicin—hematologic cancer	5.13e-05	0.00014	CcSEcCtD
Dicyclomine—Somnolence—Epirubicin—hematologic cancer	5.12e-05	0.00014	CcSEcCtD
Dicyclomine—Anorexia—Doxorubicin—hematologic cancer	5.08e-05	0.000139	CcSEcCtD
Dicyclomine—Feeling abnormal—Methotrexate—hematologic cancer	5.07e-05	0.000138	CcSEcCtD
Dicyclomine—Dyspepsia—Epirubicin—hematologic cancer	5.07e-05	0.000138	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Methotrexate—hematologic cancer	5.03e-05	0.000137	CcSEcCtD
Dicyclomine—Nausea—Betamethasone—hematologic cancer	5.02e-05	0.000137	CcSEcCtD
Dicyclomine—Nausea—Dexamethasone—hematologic cancer	5.02e-05	0.000137	CcSEcCtD
Dicyclomine—Decreased appetite—Epirubicin—hematologic cancer	5e-05	0.000137	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.97e-05	0.000136	CcSEcCtD
Dicyclomine—Fatigue—Epirubicin—hematologic cancer	4.96e-05	0.000136	CcSEcCtD
Dicyclomine—Pain—Epirubicin—hematologic cancer	4.92e-05	0.000134	CcSEcCtD
Dicyclomine—Constipation—Epirubicin—hematologic cancer	4.92e-05	0.000134	CcSEcCtD
Dicyclomine—Urticaria—Methotrexate—hematologic cancer	4.89e-05	0.000133	CcSEcCtD
Dicyclomine—Dizziness—Prednisone—hematologic cancer	4.87e-05	0.000133	CcSEcCtD
Dicyclomine—Abdominal pain—Methotrexate—hematologic cancer	4.86e-05	0.000133	CcSEcCtD
Dicyclomine—Insomnia—Doxorubicin—hematologic cancer	4.82e-05	0.000132	CcSEcCtD
Dicyclomine—Paraesthesia—Doxorubicin—hematologic cancer	4.78e-05	0.000131	CcSEcCtD
Dicyclomine—Dyspnoea—Doxorubicin—hematologic cancer	4.75e-05	0.00013	CcSEcCtD
Dicyclomine—Feeling abnormal—Epirubicin—hematologic cancer	4.74e-05	0.00013	CcSEcCtD
Dicyclomine—Somnolence—Doxorubicin—hematologic cancer	4.74e-05	0.000129	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Epirubicin—hematologic cancer	4.71e-05	0.000129	CcSEcCtD
Dicyclomine—Dyspepsia—Doxorubicin—hematologic cancer	4.69e-05	0.000128	CcSEcCtD
Dicyclomine—Vomiting—Prednisone—hematologic cancer	4.68e-05	0.000128	CcSEcCtD
Dicyclomine—Rash—Prednisone—hematologic cancer	4.64e-05	0.000127	CcSEcCtD
Dicyclomine—Dermatitis—Prednisone—hematologic cancer	4.64e-05	0.000127	CcSEcCtD
Dicyclomine—Decreased appetite—Doxorubicin—hematologic cancer	4.63e-05	0.000126	CcSEcCtD
Dicyclomine—Headache—Prednisone—hematologic cancer	4.61e-05	0.000126	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.6e-05	0.000126	CcSEcCtD
Dicyclomine—Fatigue—Doxorubicin—hematologic cancer	4.59e-05	0.000125	CcSEcCtD
Dicyclomine—Urticaria—Epirubicin—hematologic cancer	4.57e-05	0.000125	CcSEcCtD
Dicyclomine—Constipation—Doxorubicin—hematologic cancer	4.56e-05	0.000124	CcSEcCtD
Dicyclomine—Pain—Doxorubicin—hematologic cancer	4.56e-05	0.000124	CcSEcCtD
Dicyclomine—Abdominal pain—Epirubicin—hematologic cancer	4.55e-05	0.000124	CcSEcCtD
Dicyclomine—Hypersensitivity—Methotrexate—hematologic cancer	4.53e-05	0.000124	CcSEcCtD
Dicyclomine—Asthenia—Methotrexate—hematologic cancer	4.41e-05	0.000121	CcSEcCtD
Dicyclomine—Feeling abnormal—Doxorubicin—hematologic cancer	4.39e-05	0.00012	CcSEcCtD
Dicyclomine—Nausea—Prednisone—hematologic cancer	4.37e-05	0.000119	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.36e-05	0.000119	CcSEcCtD
Dicyclomine—Pruritus—Methotrexate—hematologic cancer	4.35e-05	0.000119	CcSEcCtD
Dicyclomine—Hypersensitivity—Epirubicin—hematologic cancer	4.24e-05	0.000116	CcSEcCtD
Dicyclomine—Urticaria—Doxorubicin—hematologic cancer	4.23e-05	0.000116	CcSEcCtD
Dicyclomine—Abdominal pain—Doxorubicin—hematologic cancer	4.21e-05	0.000115	CcSEcCtD
Dicyclomine—Asthenia—Epirubicin—hematologic cancer	4.13e-05	0.000113	CcSEcCtD
Dicyclomine—Pruritus—Epirubicin—hematologic cancer	4.07e-05	0.000111	CcSEcCtD
Dicyclomine—Dizziness—Methotrexate—hematologic cancer	4.07e-05	0.000111	CcSEcCtD
Dicyclomine—Hypersensitivity—Doxorubicin—hematologic cancer	3.92e-05	0.000107	CcSEcCtD
Dicyclomine—Vomiting—Methotrexate—hematologic cancer	3.91e-05	0.000107	CcSEcCtD
Dicyclomine—Rash—Methotrexate—hematologic cancer	3.88e-05	0.000106	CcSEcCtD
Dicyclomine—Dermatitis—Methotrexate—hematologic cancer	3.88e-05	0.000106	CcSEcCtD
Dicyclomine—Headache—Methotrexate—hematologic cancer	3.85e-05	0.000105	CcSEcCtD
Dicyclomine—Asthenia—Doxorubicin—hematologic cancer	3.82e-05	0.000104	CcSEcCtD
Dicyclomine—Dizziness—Epirubicin—hematologic cancer	3.81e-05	0.000104	CcSEcCtD
Dicyclomine—Pruritus—Doxorubicin—hematologic cancer	3.77e-05	0.000103	CcSEcCtD
Dicyclomine—Vomiting—Epirubicin—hematologic cancer	3.66e-05	0.0001	CcSEcCtD
Dicyclomine—Nausea—Methotrexate—hematologic cancer	3.65e-05	9.98e-05	CcSEcCtD
Dicyclomine—Rash—Epirubicin—hematologic cancer	3.63e-05	9.91e-05	CcSEcCtD
Dicyclomine—Dermatitis—Epirubicin—hematologic cancer	3.63e-05	9.9e-05	CcSEcCtD
Dicyclomine—Headache—Epirubicin—hematologic cancer	3.61e-05	9.85e-05	CcSEcCtD
Dicyclomine—Dizziness—Doxorubicin—hematologic cancer	3.52e-05	9.62e-05	CcSEcCtD
Dicyclomine—Nausea—Epirubicin—hematologic cancer	3.42e-05	9.34e-05	CcSEcCtD
Dicyclomine—Vomiting—Doxorubicin—hematologic cancer	3.39e-05	9.25e-05	CcSEcCtD
Dicyclomine—Rash—Doxorubicin—hematologic cancer	3.36e-05	9.17e-05	CcSEcCtD
Dicyclomine—Dermatitis—Doxorubicin—hematologic cancer	3.36e-05	9.16e-05	CcSEcCtD
Dicyclomine—Headache—Doxorubicin—hematologic cancer	3.34e-05	9.11e-05	CcSEcCtD
Dicyclomine—Nausea—Doxorubicin—hematologic cancer	3.16e-05	8.64e-05	CcSEcCtD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3R1—hematologic cancer	1.17e-05	0.000156	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CDKN2B—hematologic cancer	1.16e-05	0.000155	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3R1—hematologic cancer	1.16e-05	0.000155	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GSTP1—hematologic cancer	1.15e-05	0.000154	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3R1—hematologic cancer	1.15e-05	0.000154	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CD86—hematologic cancer	1.14e-05	0.000152	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CD86—hematologic cancer	1.14e-05	0.000152	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—JAK2—hematologic cancer	1.13e-05	0.000151	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—JAK2—hematologic cancer	1.13e-05	0.000151	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CD86—hematologic cancer	1.13e-05	0.00015	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HES1—hematologic cancer	1.13e-05	0.00015	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HES1—hematologic cancer	1.12e-05	0.00015	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—JAK2—hematologic cancer	1.12e-05	0.000149	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NCOR1—hematologic cancer	1.12e-05	0.000149	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.12e-05	0.000149	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NCOR1—hematologic cancer	1.12e-05	0.000149	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HES1—hematologic cancer	1.11e-05	0.000148	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CSF2—hematologic cancer	1.11e-05	0.000148	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FGF1—hematologic cancer	1.11e-05	0.000148	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NCOR1—hematologic cancer	1.1e-05	0.000147	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FGF1—hematologic cancer	1.1e-05	0.000147	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CSF2—hematologic cancer	1.1e-05	0.000147	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FGF1—hematologic cancer	1.09e-05	0.000146	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CSF2—hematologic cancer	1.09e-05	0.000146	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ABCB1—hematologic cancer	1.09e-05	0.000146	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FOXO1—hematologic cancer	1.09e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—IL2—hematologic cancer	1.09e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PDGFRB—hematologic cancer	1.09e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FOXO1—hematologic cancer	1.09e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—IL2—hematologic cancer	1.09e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PDGFRB—hematologic cancer	1.08e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CB—hematologic cancer	1.08e-05	0.000144	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FOXO1—hematologic cancer	1.08e-05	0.000144	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—IL2—hematologic cancer	1.08e-05	0.000144	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PDGFRB—hematologic cancer	1.07e-05	0.000143	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CB—hematologic cancer	1.07e-05	0.000143	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PDGFRA—hematologic cancer	1.07e-05	0.000143	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PDGFRA—hematologic cancer	1.07e-05	0.000142	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—JAK1—hematologic cancer	1.07e-05	0.000142	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PRKCG—hematologic cancer	1.07e-05	0.000142	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PRKCG—hematologic cancer	1.06e-05	0.000142	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—JAK1—hematologic cancer	1.06e-05	0.000142	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CB—hematologic cancer	1.06e-05	0.000142	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—NCOR1—hematologic cancer	1.06e-05	0.000141	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GSTM1—hematologic cancer	1.06e-05	0.000141	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PDGFRA—hematologic cancer	1.06e-05	0.000141	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—JAK1—hematologic cancer	1.05e-05	0.000141	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PRKCG—hematologic cancer	1.05e-05	0.000141	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL2RA—hematologic cancer	9.97e-06	0.000133	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL2RA—hematologic cancer	9.94e-06	0.000133	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CG—hematologic cancer	9.9e-06	0.000132	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL2—hematologic cancer	9.9e-06	0.000132	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL2—hematologic cancer	9.87e-06	0.000132	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TERT—hematologic cancer	9.86e-06	0.000132	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL2RA—hematologic cancer	9.84e-06	0.000131	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TERT—hematologic cancer	9.83e-06	0.000131	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL2—hematologic cancer	9.77e-06	0.00013	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TERT—hematologic cancer	9.73e-06	0.00013	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PDGFB—hematologic cancer	9.62e-06	0.000128	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PDGFB—hematologic cancer	9.59e-06	0.000128	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PDGFB—hematologic cancer	9.5e-06	0.000127	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TSC2—hematologic cancer	9.41e-06	0.000125	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TSC2—hematologic cancer	9.38e-06	0.000125	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—MTHFR—hematologic cancer	9.36e-06	0.000125	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TSC2—hematologic cancer	9.29e-06	0.000124	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CREBBP—hematologic cancer	9.18e-06	0.000123	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FGFR3—hematologic cancer	9.05e-06	0.000121	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FGFR3—hematologic cancer	9.02e-06	0.00012	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAPK14—hematologic cancer	8.96e-06	0.00012	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FGFR3—hematologic cancer	8.93e-06	0.000119	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAPK14—hematologic cancer	8.93e-06	0.000119	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAPK14—hematologic cancer	8.84e-06	0.000118	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ESR1—hematologic cancer	8.79e-06	0.000117	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ESR1—hematologic cancer	8.76e-06	0.000117	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CD—hematologic cancer	8.71e-06	0.000116	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FN1—hematologic cancer	8.68e-06	0.000116	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ESR1—hematologic cancer	8.68e-06	0.000116	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FN1—hematologic cancer	8.65e-06	0.000115	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ALB—hematologic cancer	8.6e-06	0.000115	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—BAD—hematologic cancer	8.58e-06	0.000114	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	8.58e-06	0.000114	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FN1—hematologic cancer	8.57e-06	0.000114	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	8.55e-06	0.000114	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—BAD—hematologic cancer	8.55e-06	0.000114	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	8.5e-06	0.000113	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	8.47e-06	0.000113	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NFKBIA—hematologic cancer	8.47e-06	0.000113	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—BAD—hematologic cancer	8.47e-06	0.000113	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NOTCH1—hematologic cancer	8.39e-06	0.000112	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CD80—hematologic cancer	8.32e-06	0.000111	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	8.31e-06	0.000111	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KIT—hematologic cancer	8.31e-06	0.000111	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	8.31e-06	0.000111	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CD80—hematologic cancer	8.3e-06	0.000111	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	8.28e-06	0.00011	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KIT—hematologic cancer	8.28e-06	0.00011	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	8.28e-06	0.00011	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.25e-06	0.00011	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3R1—hematologic cancer	8.22e-06	0.00011	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CD80—hematologic cancer	8.22e-06	0.00011	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KIT—hematologic cancer	8.2e-06	0.000109	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	8.2e-06	0.000109	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	8.2e-06	0.000109	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	8.16e-06	0.000109	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	8.14e-06	0.000109	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	8.06e-06	0.000107	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	7.96e-06	0.000106	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	7.93e-06	0.000106	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CREB1—hematologic cancer	7.91e-06	0.000106	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CREB1—hematologic cancer	7.88e-06	0.000105	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CG—hematologic cancer	7.87e-06	0.000105	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	7.85e-06	0.000105	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—BRAF—hematologic cancer	7.81e-06	0.000104	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CREB1—hematologic cancer	7.81e-06	0.000104	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—BRAF—hematologic cancer	7.78e-06	0.000104	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCL2—hematologic cancer	7.74e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL6R—hematologic cancer	7.71e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCL2—hematologic cancer	7.71e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—BRAF—hematologic cancer	7.71e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	7.7e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL6R—hematologic cancer	7.69e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	7.68e-06	0.000102	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCL2—hematologic cancer	7.64e-06	0.000102	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL6R—hematologic cancer	7.62e-06	0.000102	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	7.6e-06	0.000101	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CB—hematologic cancer	7.59e-06	0.000101	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	7.35e-06	9.81e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	7.33e-06	9.78e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	7.3e-06	9.74e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CREBBP—hematologic cancer	7.29e-06	9.73e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	7.28e-06	9.71e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	7.26e-06	9.68e-05	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	7.23e-06	9.65e-05	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	7.21e-06	9.62e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	7.21e-06	9.62e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	7.15e-06	9.54e-05	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	7.14e-06	9.53e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	7.13e-06	9.51e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	7.06e-06	9.42e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FGF2—hematologic cancer	6.99e-06	9.33e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FGF2—hematologic cancer	6.97e-06	9.3e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CD—hematologic cancer	6.92e-06	9.23e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FGF2—hematologic cancer	6.9e-06	9.21e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	6.9e-06	9.2e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	6.87e-06	9.17e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ALB—hematologic cancer	6.83e-06	9.11e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	6.81e-06	9.08e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—JAK2—hematologic cancer	6.7e-06	8.94e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—JAK2—hematologic cancer	6.68e-06	8.91e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—JAK2—hematologic cancer	6.62e-06	8.83e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	6.57e-06	8.76e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTEN—hematologic cancer	6.56e-06	8.75e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	6.55e-06	8.74e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MDM2—hematologic cancer	6.54e-06	8.73e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3R1—hematologic cancer	6.53e-06	8.71e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MDM2—hematologic cancer	6.52e-06	8.7e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	6.48e-06	8.65e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MDM2—hematologic cancer	6.46e-06	8.62e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	6.37e-06	8.49e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MTOR—hematologic cancer	6.37e-06	8.49e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MTOR—hematologic cancer	6.35e-06	8.47e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	6.35e-06	8.47e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MTOR—hematologic cancer	6.28e-06	8.38e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	6.28e-06	8.38e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—EP300—hematologic cancer	6.25e-06	8.34e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	6.08e-06	8.11e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	6.06e-06	8.08e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CB—hematologic cancer	6.03e-06	8.04e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	6e-06	8e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	5.97e-06	7.97e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	5.96e-06	7.94e-05	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	5.91e-06	7.88e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	5.9e-06	7.87e-05	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	5.89e-06	7.86e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CASP3—hematologic cancer	5.86e-06	7.81e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL2—hematologic cancer	5.85e-06	7.8e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CASP3—hematologic cancer	5.84e-06	7.79e-05	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	5.83e-06	7.78e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL2—hematologic cancer	5.83e-06	7.77e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL6—hematologic cancer	5.82e-06	7.76e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL6—hematologic cancer	5.8e-06	7.74e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CASP3—hematologic cancer	5.78e-06	7.71e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL2—hematologic cancer	5.77e-06	7.7e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL6—hematologic cancer	5.74e-06	7.66e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCND1—hematologic cancer	5.7e-06	7.6e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—JUN—hematologic cancer	5.69e-06	7.59e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCND1—hematologic cancer	5.68e-06	7.58e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—JUN—hematologic cancer	5.67e-06	7.56e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCND1—hematologic cancer	5.63e-06	7.51e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—JUN—hematologic cancer	5.61e-06	7.49e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	5.51e-06	7.36e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PTEN—hematologic cancer	5.5e-06	7.34e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	5.5e-06	7.33e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PTEN—hematologic cancer	5.48e-06	7.32e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	5.44e-06	7.26e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PTEN—hematologic cancer	5.43e-06	7.24e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	5.38e-06	7.18e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	5.37e-06	7.16e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	5.36e-06	7.16e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	5.35e-06	7.14e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	5.31e-06	7.09e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	5.3e-06	7.07e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EP300—hematologic cancer	5.25e-06	7e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EP300—hematologic cancer	5.23e-06	6.98e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTEN—hematologic cancer	5.21e-06	6.95e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EP300—hematologic cancer	5.18e-06	6.91e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SRC—hematologic cancer	5.1e-06	6.81e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SRC—hematologic cancer	5.09e-06	6.78e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SRC—hematologic cancer	5.04e-06	6.72e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	4.97e-06	6.63e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—EP300—hematologic cancer	4.97e-06	6.63e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	4.95e-06	6.61e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—STAT3—hematologic cancer	4.92e-06	6.56e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NRAS—hematologic cancer	4.91e-06	6.55e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	4.9e-06	6.54e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—STAT3—hematologic cancer	4.9e-06	6.54e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NRAS—hematologic cancer	4.89e-06	6.53e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—STAT3—hematologic cancer	4.86e-06	6.48e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NRAS—hematologic cancer	4.84e-06	6.46e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	4.7e-06	6.27e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	4.69e-06	6.25e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	4.64e-06	6.19e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CA—hematologic cancer	4.63e-06	6.17e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MYC—hematologic cancer	4.57e-06	6.1e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	4.56e-06	6.08e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MYC—hematologic cancer	4.56e-06	6.08e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	4.55e-06	6.06e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MYC—hematologic cancer	4.51e-06	6.02e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	4.5e-06	6.01e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KRAS—hematologic cancer	4.22e-06	5.64e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KRAS—hematologic cancer	4.21e-06	5.62e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KRAS—hematologic cancer	4.17e-06	5.56e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	3.88e-06	5.18e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	3.87e-06	5.16e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	3.83e-06	5.11e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—AKT1—hematologic cancer	3.78e-06	5.04e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TP53—hematologic cancer	3.75e-06	5.01e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TP53—hematologic cancer	3.74e-06	4.99e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TP53—hematologic cancer	3.71e-06	4.94e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CA—hematologic cancer	3.68e-06	4.9e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HRAS—hematologic cancer	3.59e-06	4.79e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HRAS—hematologic cancer	3.58e-06	4.77e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HRAS—hematologic cancer	3.54e-06	4.73e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL6—hematologic cancer	3.44e-06	4.58e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL6—hematologic cancer	3.43e-06	4.57e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL6—hematologic cancer	3.39e-06	4.53e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—AKT1—hematologic cancer	3.17e-06	4.23e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—AKT1—hematologic cancer	3.16e-06	4.22e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—AKT1—hematologic cancer	3.13e-06	4.17e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—AKT1—hematologic cancer	3e-06	4.01e-05	CbGpPWpGaD
